Binghe Xu

home / authors / binghe-xu

Articles

21 Ribociclib (RIB) + Nonsteroidal Aromatase Inhibitor (NSAI) as Adjuvant Treatment in Patients (pts) With HR+/HER2– Early Breast Cancer (EBC): Final Invasive Disease-Free Survival (iDFS) Analysis From the NATALEE Trial

21 Ribociclib (RIB) + Nonsteroidal Aromatase Inhibitor (NSAI) as Adjuvant Treatment in Patients (pts) With HR+/HER2– Early Breast Cancer (EBC): Final Invasive Disease-Free Survival (iDFS) Analysis From the NATALEE Trial

Gabriel N. Hortobagyi, MD, FACP;Daniil Stroyakovskiy;Denise A. Yardley, MD;Chiun-Sheng Huang;Peter A. Fasching;John Crown;Aditya Bardia, MD, MPH;Stephen Chia;Seock-Ah Im;Miguel Martin, MD, PhD;Sherene Loi, MD, PhD;Binghe Xu;Sara A. Hurvitz, MD;Carlos Barrios;Michael Untch, MD, PhD;Rebecca Moroose;Frances Visco;Federico Parnizari;Farhat Ghaznawi;Zheng Li;Sorcha Waters;Arunava Chakravartty;Dennis J. Slamon, MD, PhD
August 7th 2024
30 Datopotamab Deruxtecan (Dato-DXd) vs Chemotherapy in Previously-Treated Inoperable or Metastatic Hormone Receptor–Positive, HER2-Negative (HR+/HER2–) Breast Cancer (BC): Primary Results From the Randomised Phase 3 TROPION-Breast01 Trial

30 Datopotamab Deruxtecan (Dato-DXd) vs Chemotherapy in Previously-Treated Inoperable or Metastatic Hormone Receptor–Positive, HER2-Negative (HR+/HER2–) Breast Cancer (BC): Primary Results From the Randomised Phase 3 TROPION-Breast01 Trial

Hope S. Rugo, MD;Aditya Bardia, MD, MPH;Komal Jhaveri;Seock-Ah Im;Senia Pernas;Michelino De Laurentiis;Shusen Wang;Noelia Martínez Jañez;Giuliano Borges;David W. Cescon;Masaya Hattori;Yen-Shen Lu;Erika P. Hamilton, MD;Qingyuan Zhang;Junji Tsurutani;Kevin Kalinsky, MD, MS;Lu Xu;Neelima Denduluri;Binghe Xu;Barbara Pistilli
July 20th 2024

Latest Updated Articles

NSABP B-42 trial results show that the assay was predictive of extended letrozole therapy response, identifying a patient subset with improved outcomes.
Published: August 9th 2024 | Updated: August 14th 2024
Gene Assay May Predict Extended Letrozole Benefits in Breast Cancer Subsets
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Published: June 2nd 2024 | Updated: June 3rd 2024
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Data from the CheckMate-67T trial support the biologics license application for subcutaneous nivolumab in multiple solid tumors.
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab in Solid Tumor Indications
Patient With Supraglottic Squamous Cell Carcinoma Develops Painful Swelling on Both Great Toes
Published: August 26th 2011 | Updated: September 8th 2024
Patient With Supraglottic Squamous Cell Carcinoma Develops Painful Swelling on Both Great Toes
Neonate With a Soft, Yellowish-Colored Plaque on the Temple
Published: July 16th 2011 | Updated: September 8th 2024
Neonate With a Soft, Yellowish-Colored Plaque on the Temple
Regardless of T790M status, lazertinib hindered the progression of intracranial metastases after unsuccessful EGFR TKI treatment in patients with EGFR-mutated NSCLC.
Published: August 29th 2024 | Updated: September 8th 2024
Lazertinib Shows Encouraging Intracranial ORR in EGFR NSCLC with CNS Metastases